A Phase III study of heat shock protein-peptide complex (HSPPC-96) [vitespen; Oncophage] versus physician's choice including interleukin-2 and/or dacarbazine/temozolmide-based therapy and/or complete tumor resection in stage IV melanoma

Trial Profile

A Phase III study of heat shock protein-peptide complex (HSPPC-96) [vitespen; Oncophage] versus physician's choice including interleukin-2 and/or dacarbazine/temozolmide-based therapy and/or complete tumor resection in stage IV melanoma

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Dacarbazine; Interleukin-2; Temozolomide; Vitespen
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 06 Sep 2012 Planned End Date (1 Dec 2005) added as reported by ClinicalTrials.gov record.
    • 20 Feb 2008 Results have been published.
    • 17 Jul 2006 Results reported at ASCO.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top